Remdesivir Research Progress: An Overview of the Emerging Evidence

References

1. Al Mosawi AJ. Bat-Human Coronaviruses: A Global Health Problem and a Therapeutic Challenge. Journal of Medical Clinical Case Reports. 2020;2(2). 1-3. doi: 10.5281/zenodo.3878405
2. Al Mosawi AJ. The Use of the Available Research Evidence to Crack the Padlock of Sars-CoV-2. Journal of Virology Research & Reports. 2020;1(1): 1-8. doi: 10. 5281/ zenodo.3970844
3. Al Mosawi AJ. Bat-human coronaviruses: Keys to the therapeutic challenge. 1st ed. Saarbrücken; LAP Lambert Academic Publishing: 2020.
4. Al Mosawi AJ. Bat-human Coronaviruses: Keys to The Therapeutic Challenge. 1st ed. Baghdad; Iraq Headquarter of Copernicus Scientists International Panel Publishing: 2020.
5. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463. PMID: 26934220; PMCID: PMC5551389.
6. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. doi: 10.1126/scitranslmed.aal3653. PMID: 28659436; PMCID: PMC5567817.
7. Maria LA, Erica LA, Amy CS, Rachel LG, Timothy PS, Xiaotao L, Everett CS, James BC, Joy YF, Robert J, Adrian SR, Tomas C, Dustin S, Richard LM, Michael OC, Ralph SB, Mark RD. Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2): e00221-18. PMID: 29511076. doi: 10.1128/ mBio. 00221-18
8. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019 Apr;21(4):271-281. doi: 10.1177/1098612X19825701. Epub 2019 Feb 13. PMID: 30755068; PMCID: PMC6435921.
9. Emmie de W, Friederike F, Jacqueline C, Robert J, Atsushi O, Tina T, Dana S, Tomas C, Heinz F. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12): 6771-6776. PMID: 32054787. doi:10.1073/pnas.1922083117
10. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Erratum in: Lancet. 2020 May 30;395(10238):1694. PMID: 32423584; PMCID: PMC7190303.
11. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Oct 8:NEJMoa2007764. doi: 10.1056/NEJMoa2007764. Epub ahead of print. PMID: 32445440; PMCID: PMC7262788.
12. Al-Mosawi AJ. Использование данных исследований для взлома замка SARS-CoV-2 (Russian edition) Sciencia Scripts: 2020.
13. Al-Mosawi AJ. Utilização de provas de investigação para rachar o cadeado da SRA-CoV-2 (Portuguese edition). Edições Nosso Conhecimento: 2020.
14. Al-Mosawi AJ. Użycie dowodów naukowych do złamania kłódki SARS-CoV-2 (Polish edition) Wnictwo Nasza Wiedza: 2020.
15. Al-Mosawi AJ. Gebruik van onderzoeksmateriaal voor het kraken van het hangslot van SARS-CoV-2 (Dutch edition). Uitgeverij Onze kennis: 2020.
16. Al-Mosawi AJ. Utilizzare le prove della ricerca per rompere il lucchetto della SARS-CoV-2 (Italian edition) Edizioni Sapien: 2020.
17. Al-Mosawi AJ. Utilisation des résultats de la recherche pour briser le cadenas du SRAS-CoV-2 (French edition) Editions Notre Savoir: 2020.
18. Al-Mosawi AJ. El uso de pruebas de investigación para romper el candado del SARS-CoV-2 (Spanish edition). Ediciones Nuestro Conocimiento: 2020.
19. Al-Mosawi AJ. Verwendung von Forschungsergebnissen zum Knacken des Vorhängeschlosses von SARS-CoV-2 (German edition) Verlag Unser Vissen: 2020.